# Early phase 1 Lupus Erythematosus: 24 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 24 trials in early phase 1 for Lupus Erythematosus, Systemic that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Early phase 1 Lupus Erythematosus, Systemic trials: 24 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/early-phase-1/lupus-erythematosus-systemic

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 24
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 5, 2026 | NCT07748156 | SNC116 Therapy for Refractory Systemic Lupus Erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Early phase 1 | Not yet recruiting | Systemic Lupus Erythematosus | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748156) |
| June 29, 2026 | NCT07674147 | RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Not yet recruiting | Autoimmune Diseases, SLE - Systemic Lupus Erythematosus, SSc-Systemic Sclerosis, IIM- Idiopathic Inflammatory... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674147) |
| June 5, 2026 | NCT07629596 | Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B... | Circunited BioPharma (Shenzhen) Co., Ltd. | Early phase 1 | Recruiting | Systemic Lupus Erythematosus, Autoimmune Hemolytic Anemia (AIHA) | 5 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07629596) |
| June 1, 2026 | NCT07617740 | IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE) | Peking University People's Hospital | Early phase 1 | Recruiting | REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617740) |
| May 19, 2026 | NCT07596680 | CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases | Nanjing Bioheng Biotech Co., Ltd. | Early phase 1 | Not yet recruiting | SLE - Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07596680) |
| April 13, 2026 | NCT07526350 | MTS109 in Patients With Refractory Autoimmune Diseases | Shanghai Changzheng Hospital | Early phase 1 | Recruiting | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis (SSc), ANCA-Associated Vasculitis... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526350) |
| March 24, 2026 | NCT07490041 | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric... | The Children's Hospital of Zhejiang University School of Medicine | Early phase 1 | Recruiting | Rheumatic Diseases, Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese), Systemic Lupus... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490041) |
| January 14, 2026 | NCT07339332 | A Clinical Study Exploring the Safety, Efficacy and Cell Metabolic Dynamics of Universal CD19 / 20 Car-t Cell Injection in Moderate to... | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Early phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339332) |
| December 24, 2025 | NCT07301164 | Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases | Peking University Third Hospital | Early phase 1 | Recruiting | System Lupus Erythematosus, Systemic Sclerosis (SSc), Inflammatory Myositis, Antiphospholipid Syndrome, ANCA Associated... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07301164) |
| December 10, 2025 | NCT07274059 | Allogeneic UCB-derived CAR-T for SLE | Chengdu Ucello Biotechnology Co., Ltd. | Early phase 1 | Recruiting | SLE - Systemic Lupus Erythematosus | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07274059) |
| December 5, 2025 | NCT07266337 | CD19/BCMA CAR-T for SLE | Chengdu Ucello Biotechnology Co., Ltd. | Early phase 1 | Not yet recruiting | SLE - Systemic Lupus Erythematosus | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07266337) |
| November 24, 2025 | NCT07246096 | Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory... | Changhai Hospital | Early phase 1 | Recruiting | Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjögren Syndrome, Rheumatoid Arthritis... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07246096) |
| September 26, 2025 | NCT07193810 | A Study of CC312 for Relapsed/Refractory Autoimmune Diseases | CytoCares Inc | Early phase 1 | Recruiting | SLE - Systemic Lupus Erythematosus, IIM- Idiopathic Inflammatory Myopathies, SSc-Systemic Sclerosis | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07193810) |
| September 16, 2025 | NCT07174843 | An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases | Shanghai Cell Therapy Group Co.,Ltd | Early phase 1 | Recruiting | Idiopathic Inflammatory Myopathies(IIM), Immune Thrombocytopenia(ITP), Systemic Lupus Erythematosus(SLE) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07174843) |
| August 6, 2025 | NCT07107659 | Safety and Efficacy of ONT01 in Lupus | Hospital for Special Surgery, New York | Early phase 1 | Recruiting | Lupus Nephritis (LN), Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Lupus Nephritis - World Health... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07107659) |
| May 14, 2025 | NCT06970951 | Early Clinical Study of UTAA91 Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early phase 1 | Not yet recruiting | Systemic Lupus Erythematosus, Rheumatoid Arthritis, Dry Syndrome, Idiopathic Inflammatory Myopathies, Systemic Sclerosis | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06970951) |
| April 27, 2025 | NCT06946485 | Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Early phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06946485) |
| April 9, 2025 | NCT06920433 | UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Systemic Lupus Erythematosus | Zhejiang University | Early phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06920433) |
| March 21, 2025 | NCT06888960 | Safety Study of CC312 in Autoimmune Disease Patients | CytoCares Inc | Early phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathy (IIM), Systemic Sclerosis (SSc), Rheumatoid... | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06888960) |
| December 2, 2024 | NCT06711146 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research | Zhejiang University | Early phase 1 | Recruiting | Systemic Lupus Erythematosus | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06711146) |
| August 12, 2024 | NCT06548607 | Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases | Nanjing Bioheng Biotech Co., Ltd. | Early phase 1 | Recruiting | SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06548607) |
| May 17, 2024 | NCT06420154 | The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases | First Affiliated Hospital of Wenzhou Medical University | Early phase 1 | Not yet recruiting | Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated... | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06420154) |
| March 18, 2024 | NCT06316791 | Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases | Juventas Cell Therapy Ltd. | Early phase 1 | Recruiting | Lupus Erythematosus, Systemic | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06316791) |
| August 24, 2023 | NCT06010472 | An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus | Changhai Hospital | Early phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06010472) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Nanjing Bioheng Biotech Co., Ltd. | 2 |
| Zhejiang University | 2 |
| Changhai Hospital | 2 |
| The Children's Hospital of Zhejiang University School of Medicine | 2 |
| The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 2 |
| CytoCares Inc | 2 |
| Chengdu Ucello Biotechnology Co., Ltd. | 2 |
| Juventas Cell Therapy Ltd. | 1 |
| First Affiliated Hospital of Wenzhou Medical University | 1 |
| Hospital for Special Surgery, New York | 1 |
| Shanghai Changzheng Hospital | 1 |
| [PersonGen BioTherapeutics (Suzhou) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/persongen-biotherapeutics-suzhou-co-ltd) | 1 |
| Peking University People's Hospital | 1 |
| Shanghai Cell Therapy Group Co.,Ltd | 1 |
| Peking University Third Hospital | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Circunited BioPharma (Shenzhen) Co., Ltd. | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 23 |
| United States | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric neurology practices in the United States](https://specstream.ai/data/businesses/pediatric-neurology-practices/united-states)
- [Arabian restaurants in the United States](https://specstream.ai/data/businesses/arabian-restaurants/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Podiatrists in the United States](https://specstream.ai/data/businesses/podiatrists/united-states)
- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [Furniture wholesalers in the United States](https://specstream.ai/data/businesses/furniture-wholesalers/united-states)
